Skip to main content
Premium Trial:

Request an Annual Quote

Rigaku Creates Contract Protein Crystallography Subsidiary

NEW YORK, Nov. 25 (GenomeWeb News) - Rigaku of Tokyo, Japan, said today that it has converted its X-ray crystallography contract services and consulting division into an independent, wholly owned subsidiary called PharmAxess.

PharmAxess is capitalized at 30 million yen ($274,000) and located in Harima Science Garden City, home to Japan's SPring-8 (SP-8) synchrotron. The company will offer contract protein crystallography services by leasing time at SP-8 or using Rigaku's in-house HomeLab LightSource X-ray diffraction systems.

Contract services will be based upon milestone payments. Rigaku said the subsidiary should see sales of 200 million yen ($1.8 million) in 2004.

Yukiteru Katsube, former head of the Institute for Protein Research at Osaka University, will become president and CEO of PharmAxess, which will initially employ 10 staffers.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.